NEUROTROPHIN-4 5, BRAIN-DERIVED NEUROTROPHIC FACTOR, AND NEUROTROPHIN-3 PROMOTE SURVIVAL OF CULTURED VESTIBULAR GANGLION NEURONS AND PROTECT THEM AGAINST NEUROTOXICITY OF OTOTOXINS/
Jl. Zheng et al., NEUROTROPHIN-4 5, BRAIN-DERIVED NEUROTROPHIC FACTOR, AND NEUROTROPHIN-3 PROMOTE SURVIVAL OF CULTURED VESTIBULAR GANGLION NEURONS AND PROTECT THEM AGAINST NEUROTOXICITY OF OTOTOXINS/, Journal of neurobiology, 28(3), 1995, pp. 330-340
The ability of neurotrophin-4/5 (NT-4/5), brain-derived neurotrophic f
actor( BDNF), neurotrophin-3 (NT-3), and nerve growth factor (NGF) to
promote survival of postnatal rat vestibular ganglion neurons (VGNs) w
as examined in dissociated cell cultures. Of the four neurotrophins, N
T-4/5 and BDNF were equally effective but more potent than NT-3 in pro
moting the survival of VGNs. In contrast, NGF showed no detectable eff
ects. As expected, TrkB-IgG (a fusion protein of extracellular domain
of TrkB and Fc domain of human immunoglobulin G) specifically inhibite
d the survival-promoting effects by NT-4/5 or BDNF and TrkC-IgG fusion
protein completely blocked that of NT-3. Immunohistochemistry with Tr
kB, TrkA, and p75 antisera revealed that VGNs made TrkB and p75 protei
ns, but not TrkA protein. Ototoxic therapeutic drugs such as cisplatin
and gentamicin often induce degeneration of hair cells and ganglion n
eurons in both auditory and vestibular systems that leads to impairmen
t of hearing and balance. When cisplatin and gentamicin were added to
the dissociated VGN culture in which the hair cells were absent, addit
ional cell death of VGNs was induced, suggesting that the two ototoxin
s may have a direct neurotoxic effect on ganglion neurons in addition
to their known toxicity on hair cells. However, if the cultures were c
o-treated with neurotrophins, NT-4/5, BDNF, and NT-3, but not NGF, pre
vented or reduced the neurotoxicity of the two ototoxins. Thus, the th
ree neurotrophins are survival factors for VGNs and are implicated in
the therapeutic prevention of VGN loss caused by injury and ototoxins.
(C) 1995 John Wiley & Sons, Inc.